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Intramembrane-cleaving proteases are required for reverse
signaling and membrane protein degradation. A major class of
these proteases is represented by the GXGD-type aspartyl pro-
teases. GXGD describes a novel signature sequence that distin-
guishes these proteases from conventional aspartyl proteases.
Members of the family of the GXGD-type aspartyl proteases are
the Alzheimer disease-related -secretase, the signal peptide
peptidases and their homologs, and the bacterial type IV
prepilin peptidases. We will describe the major biochemical
and functional properties of the signal peptide peptidases and
their relatives. We then compare these properties with those
of -secretase and discuss common mechanisms but also
point out a number of substantial differences.
During the last years, a number of intramembrane-cleaving
proteases termed I-CLiPs3 have been identified (1). I-CLiPs are
generally involved in regulated intramembrane proteolysis (2).
Upon shedding of a large part of the ectodomain of membrane
proteins, the remaining membrane-retained stub is cleaved by
specialized proteases within the hydrophobic lipid membrane.
Generally, this cleavage can have two predominant biological
functions: first, signaling via the liberated ICD within the sub-
strate-expressing cell (reverse signaling) (2); and second, deg-
radation of membrane-retained stubs, which are not required
for any further biological function (3). I-CLiPs of three protease
classes, metalloproteases, serine proteases, and aspartyl pro-
teases, have been discovered so far (see accompanying minire-
view by Wolfe (44)).
Intramembrane-cleaving aspartyl proteases are represented
by the class of the GXGD-type proteases (4). These are uncon-
ventional aspartyl proteases that, like the conventional aspartyl
proteases, utilize two critical aspartyl residues for peptide bond
cleavage. However, in contrast to the conventional proteases,
the critical aspartyl residues are located within two TMDs (Fig.
1A). Moreover, these aspartyl residues are embedded in active-
site motifs that are completely different from those of conven-
tional aspartyl proteases. The class of GXGD-type aspartyl pro-
teases is currently represented by three different protease
families, the most prominent of which is the PS family, pro-
viding the catalytically active subunit of -secretase (Fig. 1A)
(4). PS/-secretase is the I-CLiP that liberates amyloid
-peptide, the major component of senile plaques in Alzhei-
mer disease patients (5). In addition, the bacterial type IV
prepilin peptidases also belong to the class of the GXGD-
type proteases (6). Besides these two protease families, two
additional subfamilies of related proteases that also belong
to the GXGD-type aspartyl protease family have been iden-
tified. These include SPP as well as the SPP homologs, the
SPP-like (SPPL) proteases (Fig. 1A) (7, 8).
We will first describe the biochemical, functional, and struc-
tural properties of SPP familymembers. By comparison of these
properties, we will then identify common mechanisms of in-
tramembrane proteolysis by GXGD-type proteases but also
point out some fundamental differences.
Intramembrane Proteolysis by SPP and SPPL Family
Members
An SPP activity capable of cleaving within the hydrophobic
environment of the membrane has been proposed for a long
time and was thought to be involved in signal peptide degrada-
tion (9), generation of cell-surface histocompatibility antigen
HLA–E epitopes (10), and processing of the hepatitis C virus
polyprotein (11). In these cases, SPP generates peptide frag-
ments either to ensure their release from the membrane and to
allow their subsequent degradation or to form functional small
peptides involved in immune surveillance and virus invasion.
Human SPP was biochemically identified upon affinity labeling
using a photocross-linkable derivative of the SPP inhibitor 1,3-
bis[(benzyloxycarbonyl-L-leucyl-L-leucyl)amino]acetone ((Z-
LL)2-ketone) (7). This revealed a 42-kDa multi-TMD protein
termed SPP. A data bank search identified five additional SPP
homologs, SPPL2a/b/c, SPPL3, and SPPL4 (occurring only in
yeast), defining the SPPL family (7, 8, 12). Although SPP/SPPL
proteases lack obvious sequence homologies to other proteins,
they all share a YD motif as well as the GXGD motif in two
neighboring TMDs and additionally the PAL sequence, located
in their most C-terminal TMD (Fig. 1A) (7, 8, 12, 13). These
three conserved domains are required for the proteolytic activ-
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ity of PS (5) and SPP (7, 14). The YD and GXGDmotifs provide
the critical aspartate residues required for the protease activity
and represent novel active-site signature sequences not present
in any of the conventional aspartyl proteases. A direct contri-
bution of the PAL motif to the catalytic center is supported by
the finding that a transition state analog inhibitor fails to bind to
SPP and PS upon mutagenesis of the PAL sequence (15). It is
currently unknown how the PAL domain affects SPP activity;
however, one may assume a close proximity of all three con-
served domains in the native enzyme forming the catalytic cen-
ter. Indeed, this was recently demonstrated for PS (16). As for
PS (17), mutagenesis of the aspartate residue within the GXGD
motif leads to inhibition of SPP/SPPL (7, 14), and in zebrafish,
expression of GXGD aspartate mutants phenocopies a mor-
pholino-mediated knockdown of the respective SPP family
member (14). Interestingly, the two active-site domains are in
oppositemembrane orientation in SPPs comparedwith PS (Fig.
1A) (18, 19). In line with the findings described above, the
C-terminal region of SPP, which contains all three highly con-
servedmotifs, was found to be suffi-
cient for proteolytic activity (20).
SPP family members apparently
do not require any other cofactors
for their proteolytic activity (7)
because, in contrast to PS, which
needs three additional proteins to
exert intramembrane proteolysis
(Fig. 1A) (5, 21), overexpression of
SPP family members leads to a sig-
nificant increase in proteolytic turn-
over of a substrate (18, 22, 23). How-
ever, it has been claimed that SPP
forms homodimers (24). Homodimer
formation was demonstrated by glyc-
erol gradient centrifugation and
co-immunoprecipitation of differen-
tially tagged SPP species (24). Strik-
ingly, the homodimer was selectively
labeled by an active-site inhibitor,
strongly supporting the notion that
dimerization is required for biological
activity. However, one has to keep in
mind that SPP is a very hydrophobic
membrane protein; thus, artificial
dimer formation may occur. Indeed,
in a later studyusing adifferent inhib-
itor, selective labeling of the mono-
mer was observed (25). Thus, more
research is required toprove the func-
tional relevance of dimer formation.
Members of the SPP family
apparently accept only membrane
proteins of type II orientation as
substrates (Fig. 1B). Obviously, all
signal peptides adopt a type II orien-
tation during cotranslation into the
ER and are therefore preferred sub-
strates of SPP (7). Consistent with
their substrate preference, SPP is located predominantly within
the ER (14, 22). Whether or not SPP may be actively retained
within the ER by its putative KKXX retention signal (7) is cur-
rently unknown. In Caenorhabditis elegans, the IMPAS gene,
which encodes the worm SPP, is required for molting. Interest-
ingly, the IMPASknockdownphenotype is rescued by the hom-
olog of the human lipoprotein receptor-related protein, which
is known to be involved in cholesterol and lipoprotein homeo-
stasis (12). However, a substrate of IMPAS has so far not been
identified. Substrates for the ER-located SPPL familymembers,
SPPL3 (14) and SPPL2c (22), are currently also not known,
although it is tempting to speculate that they, in analogy to SPP,
turn over signal peptides as well. However, one needs to keep in
mind that SPPL3 may also occur within later compartments
(22). SPPL2a and SPPL2b accumulate in the Golgi apparatus,
on the plasma membrane, and within endosomes (14, 22).
TNF (Fig. 1B) (22, 23), the Fas ligand (26), and Bri2 (Itm2b)
(27) are the only known substrates for SPPL2a/b. All three sub-
strates undergo ectodomain shedding by a protease of the
FIGURE 1. A, schematic representation of SPPL2a/b, a member of the SPP/SPPL family, and PS, the catalytic core
of the -secretase. Note the opposite topology of the active sites (indicated by arrows) of the two proteases and
their substrates, APP for PS and TNF for SPPL2a/b. B, proteolytic processing of APP and TNF. Shedding
releases the extracellular part of APP (APPs) and TNF (TNF soluble). In the case of APP, a C-terminal fragment
(APP CTF), and in case of TNF, an N-terminal fragment (TNF NTF) are produced. These membrane-bound
fragments are substrate to intramembrane cleavage by PS or SPPL2a/b, respectively, releasing small peptides
to the extracellular space (A and TNF C-domain, respectively) and to the cytosol (APP intracellular domain
(AICD) and TNF ICD), respectively). TNF FL, full-length TNF.
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ADAM (a disintegrin andmetalloprotease) family (Fig. 1B) (22,
23, 26, 27). Apparently, shedding of these substrates is not abso-
lutely required for subsequent intramembrane proteolysis, but it
may greatly facilitate this cleavage (45). In that regard, it is inter-
esting to note that phorbol ester-induced shedding of TNF sig-
nificantly stimulates intramembrane proteolysis of TNF (22),
suggesting that shedding supports subsequent proteolysis. In
line with this finding, SPP cleavage of the preprolactin signal
sequence is very efficient upon previous cleavage by signal pep-
tidase. However, even a mutant preprolactin substrate that is
not processed by signal peptidase still undergoes intramem-
brane proteolysis to some extent (28).
Because ADAM-mediated shedding occurs predominantly
on the plasmamembrane, SPPL2a and SPPL2bmay favor cleav-
ing their truncated substrates at the cell surface or upon re-in-
ternalization within endosomes. The resulting ICD of the
SPPL2a/b cleavage may be involved in nuclear signaling. Spe-
cifically, the ICD of TNF has been shown to stimulate expres-
sion of the pro-inflammatory cytokine interleukin-12 (22). Sim-
ilarly, the ICD of the Fas ligand translocates to the nucleus,
where it may suppress gene transcription (26). Although spe-
cific signalingmechanisms have been identified for SPPL2a and
SPPL2b, one may still expect that these proteases also perform
a “membrane-proteasome”-like function for the degradation of
type II-oriented membrane protein stubs.
The substrates of SPP/SPPL family members may require
unwinding of their -helical TMD prior to endoproteolysis.
For SPP, this is apparently promoted by helix-breaking res-
idues within the hydrophobic core of the signal peptides
(28), although such residues can be deleted in the TMD of
TNF without significantly affect-
ing intramembrane proteolysis by
SPPL2b.4 Unfortunately, structural
information is not available for any of
the SPP family members. Therefore,
it is difficult to predict how the
intramembrane cleavage is mecha-
nistically performed and how the
essential water molecules gain access
to the hydrophobic environment.
However, a single intramembrane cut
does not seem to be sufficient for the
release of the TNF ICD (Fig. 2). In
that case, multiple cleavages occur-
ring within the membrane have been
reported (23). These multiple cuts
may be required to facilitate the effi-
cient release of the cleavage products
from the membrane. Whether such
multiple cleavages occur with other
substrates as well is unknown. How-
ever, a synthetic substrate for SPPwas
shown to undergo one major as well
as several other minor intramem-
brane cuts (25). Nevertheless, it is too
early to speculate if such multiple
intramembrane cleavages are a gen-
eral phenomenon for all SPP family
members, although very similar cleavage patterns were observed
for -secretase substrates such as APP and Notch. Here, these
cleavages are termed , , and  and occur in a sequential manner,
from  to  (Fig. 2) (see also Ref. 5).
Comparison of the Biochemical and Cellular Properties
of GXGD Proteases
The above-described biochemical, structural, and functional
properties of -secretase and members of the SPP/SPPL family
clearly point out some striking similarities, but there are also
obvious differences. The sequence homologies between the two
proteases are very limited and predominantly restricted to
three domains (Fig. 1A), which apparently all contribute to the
active site. The very limited homology suggests that SPP/SPPL
family members and PSs may have evolved by convergence and
are probably not directly related. Moreover, -secretase clearly
requires four different proteins (PS, Aph-1 (anterior pharynx-
defective 1), Pen-2 (presenilin enhancer 2), and NCT) (21) for
its activity, whereas SPP family members work either on their
own or as homodimers (7, 23, 24). Currently, there is no evi-
dence suggesting that any additional cofactors are required for
SPP/SPPL function, and studies on functional expression of
SPP/SPPL familymembers inmammalian cells and even in bac-
teria (20) may rule out essential cofactors.
Another very important difference is the opposite orienta-
tion of the active-site domains YD and GXGD (Fig. 1A) (7, 10,
19). It has been strongly argued that this difference is related to
the different orientation of the individual substrates: type I for
4 R. Fluhrer and C. Haass, unpublished data.
FIGURE 2. Multiple intramembrane cleavages are mediated by -secretase (upper) and SPPL2a/b (lower).
The known cleavage sites of -secretase in APP (upper) and SPPL2a/b in TNF (lower) are indicated by arrows.
Major cleavage sites in the APP transmembrane domain are indicated by enlarged arrows. Dashed arrows
indicate potential direction of the cleavages by the respective intramembrane protease. For APP, two parallel
product lines have been suggested, which are initiated by cleavages after amino acid 48 or 49 (5). The initiating
cleavage of -secretase liberates the APP intracellular domain (AICD) into the cytosol, whereas that of SPPL2a/b
liberates the TNF C-domain into the extracellular space.
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-secretase and type II for SPP/SPPL family members. How-
ever, although it is indeed tempting to argue in this direction, a
formal proof has so far not been obtained. If that hypothesis is
true, one has to find an opposite sequential order of the
intramembrane cleavages discussed above. An opposite ori-
entation of both substrate and active sites would suggest an
-like cleavage liberating the secreted C-domain and a -like
cleavage finally releasing the ICD of an SPP/SPPL substrate
(Figs. 1B and 2).
The regulated intramembrane proteolysis pathway im-
plies that initial shedding is required to allow substrate bind-
ing (2). The only exception of this rule so far is the family of
Rhomboid proteases (see accompanying minireview by
Wolfe (44)). -Secretase strictly follows this rule (Fig. 1B)
because only N-terminally truncated substrates are accepted
(29). Moreover, NCT is believed to mediate this size selection
and to serve as the initial substrate-docking site (30), although
that has recently been challenged (31). So far, no NCT-like fac-
tor has been identified for any of the SPP/SPPL family mem-
bers. Nevertheless, as discussed above, initial shedding events
have been reported for all known substrates of SPP/SPPL family
members. Do these substrates require shedding to allow subse-
quent intramembrane proteolysis, or can the full-length pro-
tein be cleaved as well? SPPL2b has been shown to bind sub-
stantial amounts of its full-length substrates (23, 27), quite in
contrast to -secretase, which co-isolates predominantly with
the truncated substrate only (32). One may therefore speculate
that both substrates can bind to SPPL2b, but only the trimmed
substrate can be efficiently converted. Such a mechanism indi-
cates that a truncated substratemayhave chemical or structural
properties by itself to facilitate intramembrane proteolysis. In
the absence of anNCT-like activity, unwinding of the TMDof a
truncated substrate may be energetically favored as soon as the
ectodomain has been removed. However, more research and
probably even a resolution of the structure of SPP with its sub-
strate bound may be required to finally address this point.
Major hallmarks of PS are the many FAD-related mutations,
which shift the -cleavage to amino acid 42 (or, in some rare
cases, to amino acid 43) (5, 33). These mutations generally
occur at highly conserved positions, and “artificial” mutations
can be created by mutagenesis of such amino acids. Are SPP/
SPPL family members similarly affected by amino acid ex-
changes of homologous amino acids? This has so far been
addressed only by Sato et al. (25). They found that “FAD-like”
mutations inserted in the YD and GXGD motifs of SPP
apparently decreased the general activity to some extent.
This “loss of function” or better “reduced function” corre-
lates well with observations made for FAD-associated PS1
mutations expressed in C. elegans, where they affected the
physiological function of-secretase inNotch signaling. In this
case, themutants showed a significant reduction of their ability
to rescue the Notch phenotype of worms lacking their endoge-
nous PS homolog (SEL-12) (34, 35). Moreover, it is known that
certain very aggressive PS mutations selectively affect the
-cleavage and therefore inhibit the efficient release of the ICD
required forNotch signaling (36, 37).However, so far at least for
SPP, no shift in the cleavage precision has been observed (25).
Nevertheless, the reduced function of similar mutants in SPP
and PS clearly suggests biochemical similarities of both types of
GXGD-type proteases. Such similarities, which are probably
related to structural homologies, are supported by the finding
that certain-secretase inhibitors such as L-685,458 and helical
peptides mimicking the substrate-docking site block SPP activ-
ity as well (15, 24, 25, 38, 39). Interestingly, whereas L-685,458
significantly reduced SPP activity, N-(N-(3,5-difluorophenac-
etyl)-L-alanyl-S-phenylglycine t-butyl ester (DAPT) failed to do
so (38). This may suggest different binding sites of such inhib-
itors. As discussed in Ref. 5, a subset of NSAIDs and other
compounds have been shown to exhibit a modulatory effect on
-secretase specificity by shifting the pathological cleavage
after amino acid 42 of the A domain to position 38, which
results in the production of a rather benign shorter A peptide
(40). Interestingly, the NSAIDs sulindac sulfide and indo-
methacin also shifted the SPP cleavage site of an artificial sub-
strate by one amino acid (25). Thismay demonstrate again sim-
ilar biochemical/structural properties of -secretase and SPP/
SPPL. Furthermore, this also suggests that most likely the
GXGD-type protease itself, the lipid environment of these pro-
teases, or both are targeted byNSAIDs.WhetherNSAIDs affect
the structure of the active site, as has been proposed for PS (41),
needs to be shown for SPP/SPPL family members. Because of
the substantial differences of -secretase and SPP/SPPL sub-
strates, selective NSAID binding to substrates seems to be
unlikely. Similarly, the findings by Sato et al. (25) may also rule
out Pen-2, NCT, and Aph-1 as potential binding sites because
these proteins do not interact with SPP/SPPL.
Functionally, both -secretase and SPP/SPPL family mem-
bers are I-CLiPs involved in reverse signaling (42). Such a func-
tion has now been best studied for the -secretase substrate
Notch (43) and the SPPL2a/b substrate TNF (22). In both
cases, ICDs are generated from a membrane-bound precursor
and are then employed in gene regulation. Whereas nuclear
signaling has been clearly shown for the Notch ICD, such a
signaling pathway has been only indirectly demonstrated for
the TNF ICD (22). As for -secretase, for which many sub-
strates have been observed, we also expect in the near future the
description of amuch larger repertoire of SPP/SPPL substrates.
Whether these are all involved in a physiologically relevant
signaling pathway is unlikely. As for -secretase, we also
expect that SPP family members may degrade membrane
stubs (in type II orientation) by exhibiting a membrane-pro-
teasome-like function, a biologically very important func-
tion required to exclude the clustering of cellular mem-
branes with protein stubs. Finally, essential functions of SPP
family members may be affected by -secretase inhibitors, a
fact that needs to be kept in mind for the development of safe
Alzheimer disease therapeutics.
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